Lovastatin: Immunomodulatory Value Evaluation

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
HIV Seropositivity
Interventions
DRUG

Lovastatin

Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear

OTHER

placebo

Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear

Trial Locations (1)

Unknown

Group of Immunovirology, Research Universitary Center, University of Antioquia, Medellín

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)

OTHER_GOV

collaborator

Laboratorio Clínico Congregación Mariana

OTHER

collaborator

Laboratorios Laproff S.A.

INDUSTRY

collaborator

Humax Pharmaceutical

INDUSTRY

lead

Universidad de Antioquia

OTHER